|
1
|
Epaillard N, Bassil J, Pistilli B. Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer. Cancer Treat Rev 2023; 119:102597. [PMID: 37454577 DOI: 10.1016/j.ctrv.2023.102597] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 06/29/2023] [Accepted: 07/03/2023] [Indexed: 07/18/2023]
Abstract
Breast cancer is one of the main cause of cerebral and leptomeningeal metastases, the prognosis of which remains poor to this day. Most studies excluded patients with active brain metastases (BM) and particularly with leptomeningeal metastases (LM) explaining the lack of therapeutic innovation in this area. Currently, the standard management of patients with BM of breast cancer is based on the combination of surgery, radiotherapy and systemic treatments. Recently, third-generation of Antibody-Drug Conjugates (ADCs), have revolutionized the management of metastatic breast cancer. Trastuzumab deruxtecan and Sacituzumab govitecan have indeed shown significant improvements of survival outcomes and can now be used in a wide range of breast cancer subtypes. However, few data are available on the efficacy of third-generation ADCs on BM and LM of breast cancer. As the field of ADCs is rapidly evolving, with new constructs entering the late clinical development, in this review we describe the efficacy of approved and novel promising conjugates on patients with BM and LM of breast cancer.
Collapse
Affiliation(s)
- N Epaillard
- Breast Cancer Unit, Gustave Roussy Cancer Center, 114 Rue Edouard-Vaillant, 94800 Villejuif, France
| | - J Bassil
- Breast Cancer Unit, Gustave Roussy Cancer Center, 114 Rue Edouard-Vaillant, 94800 Villejuif, France
| | - B Pistilli
- Breast Cancer Unit, Gustave Roussy Cancer Center, 114 Rue Edouard-Vaillant, 94800 Villejuif, France. https://twitter.com/barbara.pistilli@BarbaraPistill2
| |
Collapse
|
|
2
|
Hirigoyen E, Epaillard N, Chastenet M, Herve R, Dutin JP, Gustin P, Mahjoubi L. 444P Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study. Ann Oncol 2022. [PMCID: PMC9719672 DOI: 10.1016/j.annonc.2022.10.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
Affiliation(s)
- E. Hirigoyen
- Medical Oncology, CHU Poitiers - Jean Bernard Hôpital, Poitiers, France
| | - N. Epaillard
- Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - M. Chastenet
- Medical Oncology, Centre Léon Bérard, Lyon, France
| | - R.A. Herve
- Medical Oncology, CHPF - Centre Hospitalier de Polynésie Francaise - Site du Taaone-Pirae, Papeete, French Polynesia
| | - J-P. Dutin
- Medical Oncology, CHPF - Centre Hospitalier de Polynésie Francaise - Site du Taaone-Pirae, Papeete, French Polynesia
| | - P. Gustin
- Radiotherapy, CHPF - Centre Hospitalier de Polynésie Francaise - Site du Taaone-Pirae, Papeete, French Polynesia
| | - L. Mahjoubi
- Early Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
|
3
|
Epaillard N, Lusque A, Pistilli B, André F, Bachelot T, Pierga JY, Ducoulombier A, Jouannaud C, Viret F, Salabert L, Johnson A, Deluche E, Durando X, Petit T, Filleron T, Mahier Ait Oukhatar C, Dieras V, Mosele M. 260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
|
4
|
Seguí E, García de Herreros M, Auclin E, Mirallas O, Casadevall D, Rodriguez M, Epaillard N, Tagliamento M, Pilotto S, López-Castro R, Mielgo X, Urbano C, Pesántez D, Saoudi N, Bluthgen M, Masfarré L, Minatta J, Cruz C, Mezquita L, Prat A. 1681P First results of the COCO study: COVID-19 outcomes in patients with cancer. Ann Oncol 2020. [PMCID: PMC7506441 DOI: 10.1016/j.annonc.2020.08.1745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
|
5
|
Ghiglione L, Auclin E, Aguilar-Company J, Epaillard N, Casadevall Aguilar D, Masfarré L, Rodriguez Castells M, Tagliamento M, Pilotto S, Lopez Castro R, Mielgo Rubio X, Urbano Centella C, Laguna J, García-Illescas D, Bluthgen M, Gorría Puga T, Minatta J, Cruz C, Prat A, Mezquita L. 1726P Expanding the role of medical oncologist in the management of COVID-19. Ann Oncol 2020. [PMCID: PMC7506355 DOI: 10.1016/j.annonc.2020.08.1790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
|
|
6
|
Seguí E, Auclin E, Casadevall D, Aguilar-Company J, Rodriguez M, Epaillard N, Tagliamento M, Pilotto S, López-Castro R, Mielgo X, Urbano C, Rodríguez A, García-Illescas D, Bluthgen M, Masfarré L, Oliveres H, Minatta J, Marco-Hernández J, Prat A, Mezquita L. 1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score. Ann Oncol 2020. [PMCID: PMC7506416 DOI: 10.1016/j.annonc.2020.08.1778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
|
|
7
|
Bourdais R, Troussier I, Epaillard N, Chauffert-Yvart L, Gérard M, Sargos P, Riet FG, Canova CH, Jenny C, Culot F, Le Corre E, Ozsahin M, Huguet F, Bachet JB, Simon JM, Maingon P, Blais E. Chimioradiothérapie des cancers du pancréas : pourquoi et comment protéger la rate ? Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
|
8
|
Epaillard N, Troussier I, Bourdais R, Hammoudi N, Huguet F, Bachet JB, Vaillant JC, Thierry A, Gligorov J, Ozsahin M, Spano JP, Simon JM, Maingon P, Blais E. Faut-il adapter la chimioradiothérapie néoadjuvante des cancers de l’œsophage à l’histologie ? Analyse des essais de phase III. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|